{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:30:23Z","timestamp":1787247023221,"version":"build-2736575974"},"reference-count":11,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2026,8,11]]},"DOI":"10.1136\/ejhpharm-2026-005049","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:20:30Z","timestamp":1787246430000},"page":"ejhpharm-2026-005049","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Semaglutide-associated agranulocytosis requiring hospitalisation and granulocyte colony-stimulating factor: a case report"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-3910","authenticated-orcid":false,"given":"Mar\u00eda","family":"Calvo Arbeloa","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hospital Universitario de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iranzu","family":"Elcano Aguirre","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitario de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Alvarellos Outeiro","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitario de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Lison Madrona","sequence":"additional","affiliation":[{"name":"Haematology Department, Hospital Universitario de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"P\u00e9rez de Ciriza Cordeu","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Hospital Universitario de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Sarobe Carricas","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitario de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"San Miguel Elcano","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitario de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2026082010202181000_ejhpharm-2026-005049v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"2026082010202181000_ejhpharm-2026-005049v1.2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-9-200705010-00009"},{"key":"2026082010202181000_ejhpharm-2026-005049v1.3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.21307\/immunohematology-2019-103","article-title":"Drug-induced immune neutropenia\/agranulocytosis","volume":"30","author":"Curtis","year":"2014","journal-title":"Immunohematology"},{"key":"2026082010202181000_ejhpharm-2026-005049v1.4","unstructured":"World Health Organization (WHO) . The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: WHO, 2002. Available: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/002b78d5-4dfc-433c-a518-f92ebdee8706\/content"},{"key":"2026082010202181000_ejhpharm-2026-005049v1.5","unstructured":"U.S. Food and Drug Administration (FDA) . (Aripiprazole lauroxil) extended-release injectable suspension, for intramuscular use. 2015. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207533s000lbl.pdf"},{"key":"2026082010202181000_ejhpharm-2026-005049v1.6","unstructured":"European Medicines Agency . Lamotrigine 100 mg tablets (Summary of Product Characteristics). EMA; 2026. Available: https:\/\/www.medicines.org.uk\/emc\/product\/4739\/smpc"},{"key":"2026082010202181000_ejhpharm-2026-005049v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"2026082010202181000_ejhpharm-2026-005049v1.8","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039030-00004"},{"key":"2026082010202181000_ejhpharm-2026-005049v1.9","article-title":"Anti-inflammatory benefits of semaglutide: State of the art","volume":"36","author":"Yaribeygi","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"2026082010202181000_ejhpharm-2026-005049v1.10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/phar.1249","article-title":"What evidence is required for drug exposure to be causally associated with adverse events? The case for case reports published in Pharmacotherapy","volume":"33","author":"DeVane","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2026082010202181000_ejhpharm-2026-005049v1.11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/JS9.0000000000001896","article-title":"Semaglutide outperforms insulin in restoring neutrophil function against implant-related infection in diabetic and obese mice: experimental research","volume":"111","author":"Liu","year":"2025","journal-title":"Int J Surg"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2026-005049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:20:33Z","timestamp":1787246433000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2026-005049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":11,"alternative-id":["10.1136\/ejhpharm-2026-005049"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2026-005049","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}